GET DAILY SIGNALSDaxor (DXR) Analyst Target Implies +166% Upside From Current Levels
Key Takeaways
- The central price target of $22.50 is the arithmetic mean of two verified analyst price targets ($22 and $23) from Maxim Group and Lake Street, both carrying Buy ratings.
- With DXR trading near $8.46, reaching $22.50 would require a gain of roughly 166%, a very large move for a micro-cap medical technology company.
- The target range is unusually narrow ($22–$23) because only two analysts actively cover the stock, which makes the "consensus" thinner than it appears.
- The strongest supporting factor is commercial momentum for Daxor's FDA-cleared next-generation blood volume measurement platform and its expanding laboratory services footprint.
- The biggest risks are a sharply declining share price, a modest revenue base, concentration of reported profit in investment income, and a micro-cap's susceptibility to volatility.
- Readers can review the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional Tickeron pages to track developments that could affect the target.
Analyst Price Targets and Consensus View
Daxor Corporation (DXR) is a Nasdaq-listed medical instrumentation and biotechnology company best known for its BVA-100 blood volume analyzer. Because the stock is thinly covered, the average analyst price target rests on just two verified estimates: Maxim Group reiterated a Buy rating with a $22 target (most recently September 9, 2026), and Lake Street analyst Frank Takkinen has maintained a Buy rating with a $23 target (initiated in early 2026 and reiterated in May 2026). The simple average of these two figures is $22.50, which is the central target used here; the low-to-high range is $22 to $23.
Both analysts frame the stock as a high-upside opportunity tied to adoption of Daxor's blood volume diagnostic platform. In my view, the range is extremely tight, which reflects the small number of covering firms rather than unanimous confidence. Investors should treat a two-analyst "consensus" with appropriate caution; it is a directional signal, not a dense distribution of independent views. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of mid-November 2026, DXR shares traded near $8.46, close to the bottom of a 52-week range of roughly $8.24 to $14.76. The stock has fallen about 42% year to date, making the required move to $22.50 — roughly 166% above the current price — very large by any standard.
The company is a micro-cap, with a market capitalization of roughly $50 million. Its financial profile is unusual: reported revenue remains small (about $132 thousand in the quarter ended December 31, 2025), while net income has been lifted substantially by investment income, so headline profitability does not translate neatly into a core commercial earnings stream. A move of this magnitude would likely require not only sustained adoption of its diagnostic technology but also a re-rating by the market that the current price does not yet reflect.
What Could Support a Move Toward the Target
- Product momentum: Daxor has received FDA 510(k) clearance for a next-generation blood volume analyzer that delivers results roughly three times faster using about 50% less blood, a meaningful selling point for hospital and clinic adoption.
- Commercial expansion: The company has broadened its footprint through its CLIA-certified "ezBVA" send-out laboratory model and has showcased its platform at cardiology and kidney-care conferences, targeting heart failure and fluid-management applications.
- Analyst conviction: Both covering firms maintain Buy ratings well above the current price, suggesting they view the decline as a valuation disconnect rather than a deterioration in the core thesis.
What Could Prevent the Target From Being Reached
- Downward price momentum: A stock trading near a 52-week low with a roughly 42% year-to-date decline faces significant technical and sentiment headwinds.
- Small revenue base: Commercial revenue remains modest, so the path to justifying a higher valuation depends on accelerating adoption that is not yet firmly established.
- Earnings quality: Because net income has been heavily influenced by investment gains, the stock's low P/E (price-to-earnings) ratio can overstate the strength of the operating business.
- Micro-cap risk: Thin trading and low institutional coverage can produce outsized volatility and limit the ability of fundamentals alone to support a sustained re-rating.
Technical Levels and Market Structure
DXR sits near its 52-week low around $8.24, which now functions as the key support level to watch. A break below it would signal further downside, while a recovery toward the $10 psychological level and then the prior high near $14.76 would represent the first meaningful resistance zones on any path back toward analyst targets. The long-term trend remains firmly negative, meaning any advance toward $22.50 would require a decisive break of multiple prior levels before the analyst targets come into view.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though neither covering firm has published a specific timeline and horizons can differ. Investors should monitor the company's quarterly results (with an earnings report expected around November 13, 2026), any updates to analyst targets or ratings, new hospital and lab-services adoption announcements, and clinical data presentations at cardiology and kidney-care meetings. Changes in the investment portfolio that underpins reported net income also warrant attention, as do any shifts in the broader small-cap healthcare environment.
Integrating AI Tools Into My Research Process
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like DXR, these tools help me spot shifts in trend more efficiently than manual chart review and keep positions under consistent surveillance. I find them useful for complementing my own analysis without replacing it.
Final Assessment
The $22.50 target for Daxor Corporation (DXR) is a two-analyst average derived from Buy-rated targets of $22 and $23, implying a gain of roughly 166% from a price near $8.46 — a very large move. The case for it rests on commercial adoption of a next-generation diagnostic platform and expansion of laboratory services, while the case against it centers on weak price momentum, a small revenue base, and earnings quality influenced by investment income. With such thin coverage and such a wide gap between price and target, investors should weigh the bullish analyst view against the stock's unresolved downtrend and monitor earnings, adoption announcements, and analyst revisions before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 22, 2026
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where DXR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXR's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +3.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXR advanced for three days, in 141 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.952) is normal, around the industry mean (4.964). P/E Ratio (5.000) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of original medical equipment for medical personnel
Industry PharmaceuticalsOther
Advertisement